Who Will Be Making News in September?

Who Will Be Making News in September?

What’s Happening in the Month Ahead: September 2017

Ocugen, fresh off getting FDA orphan drug designation for OCU300-brimonidine to treat ocular graft rejection, will participate in the 19th annual Rodman-Renshaw Global Investment Conference September 10–12 at the Lotte New York Palace Hotel.

Pfenex Inc., developer of a Lucentis biosimilar, will also be presenting at the Rodman and Renshaw Global Investment Conference on September 12.

Second Sight Medical Products, developer of the Argus II retinal prosthesis system, will be preparing its response to the FDA’s request for more information on the Orion Cortical Visual Prosthesis System, with answers due by mid-October. The FDA granted conditional approval for the Orion device that allows two US sites to enroll up to five patients.

Nicox SA participates in Cantor Fitzgerald’s third annual healthcare conference September 25–27 in New York. Nicox’s lead candidates are Zerviate (formerly AC-170) for treatment of allergic conjunctivitis, and Vyzulta (latanoprostenebunod ophthalmic solution 0.024%) for treatment of glaucoma or ocular hypertension. It held its shareholders [meeting?]on Monday – Labor Day in the US but just another day in the office in France – in Sophia Antipolis, France.

Regenxbio has a busy slate of investor conferences in September to talk about its pending acquisition of Dimension Therapeutics and its own gene therapy programs like RGX-314 to treat wet age-related macular degeneration (AMD): the 12th annual Citi Biotech Conference September 6–7 in Boston; the 15th annual Morgan Stanley Global Healthcare Conference September 11–13 at the Grand Hyatt, New York; and the Cantor Fitzgerald Global Healthcare Conference September 25–27 at the InterContinental New York Barclay Hotel. Dimension is developing two gene therapies outside of ophthalmology. Regenxbio aims to close the acquisition by year-end.

Applied Genetic Technologies Corporation – AGTC – developer of gene therapies to treat inherited orphan disease of the eye as well as wet AMD, will host a conference call on September 13 with management to review fourth-quarter and fiscal-year results. AGTC will also present at the Cantor Fitzgerald Global Healthcare Conference on September 26.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

MicrosoftTeams-image (62)

Oyster Point Ramps Up for Tyrvaya, First Dry Eye Nasal Spray

Pod 306 Bill McPhee - Thumb

Faster, Better, Smarter, Cheaper With MacuLogix’s Bill McPhee

the oral retina drugs are coming

Six Oral Retina Drug Development Programs to Watch

OPUS Genetics

Opus Genetics: RD Fund’s First Spinout to Advance Gene Therapies for Inherited Retinal Diseases

Pod 304 - Karpecki - Gertner - Thumbnail

DIY Commercialization, with Olympic Ophthalmics’ Michael Gertner, MD

MicrosoftTeams-image (139)

OIS Glaucoma Showcase Take-Home: Glaucoma Market Poised For Growth

About The Author

Rich Kirkner

Richard Kirkner is an award-winning journalist and editorial consultant who has specialized in ophthalmology and eye care media for three decades. Based in Philadelphia, his work has been recognized with more than 40 awards for editorial excellence.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

PODCASTS